# Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

> **NCT00465816** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 611 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Nimenrix (Meningococcal vaccine 134612)
- **BIOLOGICAL:** Twinrix

## Key facts

- **NCT ID:** NCT00465816
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-11
- **Primary completion:** 2008-04-28
- **Final completion:** 2008-04-28
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00465816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00465816, "Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00465816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*